Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ocifisertib - Treadwell Therapeutics

Drug Profile

Ocifisertib - Treadwell Therapeutics

Alternative Names: CFI 400945 fumarate; CFI-400945

Latest Information Update: 22 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University Health Network
  • Developer AstraZeneca; Canadian Cancer Trials Group; Treadwell Therapeutics; University Health Network
  • Class Antineoplastics; Cyclopropanes; Ethers; Indazoles; Indoles; Morpholines; Small molecules; Spiro compounds
  • Mechanism of Action PLK4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Prostate cancer; Triple negative breast cancer
  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Preclinical Diffuse large B cell lymphoma; Uterine leiomyoma
  • No development reported Cancer

Most Recent Events

  • 20 Feb 2024 CFI 400945 receives Orphan Drug status for Acute myeloid leukaemia in USA
  • 15 Dec 2023 Efficacy and adverse events data from a phase I/II TWT-202 trial in Acute myeloid leukemia released by Treadwell Therapeutics
  • 06 Dec 2023 Treadwell Therapeutics plans a pivotal trial in Acute myeloid leukemia in 2025
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top